SEER Seer, Inc.

Nasdaq seer.bio


$ 2.14 $ -0.05 (-2.26 %)    

Friday, 17-Oct-2025 15:59:21 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.16
$ 2.18
$ 2.10 x 200
$ 2.29 x 998
$ 2.13 - $ 2.22
$ 1.62 - $ 2.63
67,053
na
121.69M
$ 2.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-04-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 seer-demonstrates-how-proteograph-platform-advances-disease-research-at-american-society-of-human-genetics-meeting

Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participat...

 seer-affirms-fy2025-sales-guidance-of-17000m-18000m-vs-17650m-est

Seer (NASDAQ:SEER) affirms FY2025 sales outlook from $17.000 million-$18.000 million to $17.000 million-$18.000 million vs $17....

 seer-q2-eps-033-beats-037-estimate-sales-410m-beat-375m-estimate

Seer (NASDAQ:SEER) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.37) by 10.81...

 reported-june-1-2025-seer-and-korea-university-launch-large-scale-study-using-proteograph-one-assay-and-mass-spectrometry-to-identify-early-onset-cancer-biomarkers-in-young-adults

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, ...

 seer-sees-fy2025-sales-17000m-18000m-vs-1903m-est

Seer (NASDAQ:SEER) sees FY2025 sales of $17.000 million-$18.000 million vs $19.03 million analyst estimate.

 seer-q4-eps-037-misses-035-estimate-sales-400m-beat-395m-estimate

Seer (NASDAQ:SEER) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.7...

 seer-q3-2024-gaap-eps-035-misses-029-estimate-sales-4032m-beat-3150m-estimate

Seer (NASDAQ:SEER) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.29) by 20....

 seer-affirms-fy2024-sales-guidance-from-1300m-1500m-to-1300m-1500m

Seer (NASDAQ:SEER) affirms FY2024 sales outlook from $13.00 million-15.00 million to $13.00 million-15.00 million.

 morgan-stanley-maintains-equal-weight-on-seer-lowers-price-target-to-3

Morgan Stanley analyst Yuko Oku maintains Seer (NASDAQ:SEER) with a Equal-Weight and lowers the price target from $7 to $3.

 seer-q2-2024-gaap-eps-035-beats-036-estimate-sales-3072m-miss-3200m-estimate

Seer (NASDAQ:SEER) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) by 2.78 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION